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Deficiencies of calcium-regulatory proteins in dialysis patients: vascular and valvular calcifications localized both in the
A novel concept of cardiovascular calcification in uremia. Dial- arterial media and within plaques. Hyperphosphatemia,
ysis patients suffer a manifold increase in cardiovascular mor- an increased calcium x phosphate ion product, and sec-tality when compared to a nonuremic population, while this
ondary hyperparathyroidism are considered to be of cen-phenomenon is not sufficiently explained by an increased prev-
tral pathophysiologic relevance, and were recently iden-alence of traditional risk factors, such as hypercholesterolemia
and hypertension. The presence of hyperphosphatemia, of an tified as independent cardiovascular risk factors in this
increased calcium x phosphate product, as well as the magni- context [4, 5]. Since a deranged calcium/phosphate bal-
tude of vascular and valvular calcifications, were recently iden-
ance correlated well with increased cardiovascular mor-tified as specific major risk factors of cardiovascular mortality
tality in dialysis patients, guidelines were produced con-in the uremic population. Furthermore, hyperphosphatemia
and an increased calcium x phosphate product could be quanti- cerning the therapeutic target levels of serum phosphate,
tatively linked to the burden of coronary artery calcification in calcium, and intact parathyroid hormone (iPTH) [5–7].
young dialysis patients, suggesting the correction of hyperphos- Goodman et al reported that more than 80% of youngphatemia as the central target for preventive therapeutic inter-
dialysis patients (aged 20–30 years) already had severevention. Recent studies in knockout mice, however, point to the
and progressive coronary artery calcifications, as detectedalternative possibility that deficiencies in calcium-regulatory
proteins may represent important pathomechanisms leading to by electron beam-computed tomography (EBCT) [8]. This
extraosseous calcifications. 2-Heremans Schmid glycoprotein study could also link the magnitude of calcification in
(Ahsg/fetuin) and matrix Gla protein (MGP) are strong inhibi-
the patients’ coronaries to hyperphosphatemia, to an in-tors of calcification in vivo. Novel evidence that deficiencies
creased serum calcium x phosphate ion product, and toof such proteins may be involved in the pathogenesis of cardio-
vascular calcifications in dialysis patients will be discussed. a high daily calcium intake, which mostly depends on
the intake of calcium-containing phosphate binders. De-
spite the fact that derangements in the calcium/phos-CARDIOVASCULAR MORTALITY IN
phate balance contribute to vascular calcifications, how-DIALYSIS PATIENTS: HYPERPHOSPHATEMIA
ever, extraosseous calcifications have also been observedAND CALCIFICATION
under conditions unexplained by hypercalcemia and hy-
Cardiovascular mortality is markedly increased in the perphosphatemia.
dialysis patient population when compared with nonure-
mic subjects, even after correction for age, gender, and
THE ROLE OF CALCIUM-REGULATORYthe presence of diabetes [1, 2]. Atherosclerosis in the dial-
ysis population has been termed “accelerated atherogen- PROTEINS IN CALCIFICATION PROCESSES
esis,” although the pathomechanisms causing the partic- The induction and inhibition of calcification processes in
ular severity and progressive nature of this complication mammalian organisms are regulated in a complex manner.
remain incompletely understood [3]. Atherosclerotic le- With regard to vascular calcification, differential regula-
sions in dialysis patients are characterized by excessive tion of calcium-regulatory proteins and osteogenic meta-
plasia within the vessel wall are well described [4, 9, 10].
MGP and Ahsg/fetuin are two potent inhibitors of extra-Key words: calcium-regulatory proteins, uremia, cardiovascular calci-
fication, MGP, AHSG/Fetuin. osseous calcium-phosphate precipitation. MGP is mainly
expressed in chondrocytes and vascular smooth muscle 2003 by the International Society of Nephrology
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cells (VSMC), and appears to act locally as a potent inhibi-
tor of cartilage and aortic calcification [11, 12]. Ahsg/
fetuin is synthesized by hepatocytes and occurs in the
extracellular space in high concentrations (0.5–1.0 g/L),
where it is responsible for approximately half of the pre-
cipitation inhibitory effect of normal serum [13–15].
Price et al recently reported the discovery of a specific
complex of Ahsg/fetuin (80%), MGP (2%), and mineral
(calcium/phosphorus; 18%), which efficiently prevented
the growth, aggregation, and precipitation of this mineral
component in etidronate-treated rats [15]. These findings
indicate that the calcification inhibitory activities of
Ahsg/fetuin and MGP may be related to their ability to
form stable complexes with nascent mineral nuclei.
Fig. 1. Severe calcifications of a coronary artery (white arrow) and ofOne potentially interesting aspect of the regulation of
the aortic valve insertion (gray arrow) in a 42-year-old dialysis patient
Ahsg/fetuin is related to its nature as a negative acute- (Agatston score: 594 [Score:  400  severe burden of coronary artery
calcification]; ECG-gated multislice spiral CT). Clinical history – Renalphase reactant. In 1979, Lebreton et al reported a large
diagnosis: chronic glomerulonephritis (no biopsy performed); start ofnumber of patients with infectious diseases, including
hemodialysis in 1988; kidney transplantation 1989–1996; re-start of he-
sepsis, pneumonia, meningitis, etc., developing low Ahsg/ modialysis in 1996 due to chronic allograft failure; arterial hypertension,
local periarticular skin calcifications on his right hand and left foot.fetuin levels during the acute inflammatory phase and
normalizing when the infection was successfully treated
[16]. Recent reports linked cardiovascular mortality of
dialysis patients and the general population, respectively,
K-deficiency may strongly amplify the local synthesis of
with a state of chronic micro-inflammation indicated by
inactive MGP antigen.
elevated C-reactive protein (CRP) levels [17, 18]. In this
context, it can be hypothesized that Ahsg/fetuin levels
AHSG/FETUIN: LESSONS FROM KNOCKOUTare potentially found decreased in affected individuals.
MICE AND BIOLOGICAL PROPERTIES
Ahsg/fetuin knockout (Ahsg/) mice (DBA2 back-MGP: GENE KNOCKOUT AND HUMAN DATA
ground) are characterized by excessive soft-tissue and
MGP knockout (MGP/) mice develop excessive cal- intraarterial calcification of a metastatic pattern [14]
cifications of the arterial media with predominant local- [S.C., unpublished data, 2002). Parenchymal organs (kid-
ization around the elastic lamellae [12]. Aortic lesions neys, lungs, heart, etc.) are affected and functionally
include massive hydroxyapatite deposition as well as car- compromised in this model. In addition to its direct calci-
tilaginous metaplasia within the vessel wall, which even- fication-inhibitory effects, however, Ahsg/fetuin possesses
tually become lethal within eight weeks due to aortic further biological properties. Ahsg/fetuin acts at the cel-
rupture and subsequent internal hemorrhage. lular level as a soluble TGF- antagonist because of
Shanahan et al demonstrated MGP distribution in hu- structural similarities to the TGF- receptor II [20]. It has
man degenerating arteries [11]. In this study, MGP ex- previously been shown that this mechanism was respon-
pression was increased in the lipid-rich areas of plaques sible for regulating cytokine-dependent osteogenesis,
[11]. These data are consistent with immunohistochemi- but it may potentially also antagonize other TGF- ef-
cal data in which MGP in atherosclerotic arteries were fects, including fibrogenesis and inhibition of cell prolif-
stained using a monoclonal antibody against human eration, respectively. Ahsg/fetuin also inhibits insulin re-
MGP [10, 19]. It is thought that local MGP up-regulation ceptor tyrosine kinase activity, and Ahsg/mice showed
may be a central mechanism counteracting and, thus, improved insulin receptor sensitivity in response to a high-
limiting progression of excessive vascular calcification. fat diet when compared with wild-type littermates [21].
Since MGP requires vitamin K-dependent -carboxyla-
tion for activation, it is speculated that subclinical vita-
UREMIC SOFT-TISSUE CALCIFICATION ANDmin K-deficiencies or local poor tissue vitamin K status
CALCIUM-REGULATORY PROTEINSmay have an influence on vascular calcification processes.
If so, MGP up-regulation in areas at risk for calcification Because uremic patients, especially diabetic uremic
would result in a higher utilization of vitamin K, and patients, develop significant media calcification, a low
in more severe vitamin K-deficiency and production of endogenous MGP synthesis (such as is seen in a number
undercarboxylated, inactive MGP. In this way, the com- of common MGP-promoter polymorphisms) [22, 23], or
poor vitamin K-dependent activation of MGP may con-bination of initial calcifications and a subclinical vitamin
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Table 1. Characteristics of the calcium-regulatory proteins matrix Gla protein (MGP) and 2-Heremans Schmid glycoprotein (Ahsg/fetuin)
MGP Ahsg/fetuin
Molecular weight 10 kD 62 kD
Serum levels 60–130 U/L 0.5–1.0 g/L
Synthesis Vascular smooth muscle cells, chondrocytes Hepatocytes
Phenotype of knockout mice Aortic media calcifications, cartilage Diffuse metastatic soft-tissue and intraarterial
calcifications, lethal due to aortic rupture calcification, impaired survival
Properties Vitamin K-dependent -carboxylation Negative acute phase reactant, TGF- antagonist,
necessary for activation inhibitor of insulin receptor tyrosine kinase activity
tribute to their disease status. Preliminary measurements K-deficiency and -carboxylated active MGP levels may
become feasible. In patients with low serum Ahsg/fetuinin dialysis patients showed elevated serum MGP levels
[24], but this assay could not discriminate the proportion levels and low calcium/phosphate precipitation inhibi-
tion levels, phosphate binder therapies would need toof -carboxylated active MGP. Therefore, these data
were not conclusive. be intensified to prevent extraosseous calcification,
whereas, vice versa, in the presence of high Ahsg/fetuinWe recently performed a cross-sectional study in 312
hemodialysis patients to examine the relationship be- levels, hyperphosphatemia levels might be tolerated tem-
porarily in this regard.tween serum Ahsg/fetuin and serum CRP levels, and
cardiovascular and all-cause mortality [25]. As indicated Second, if an activated acute-phase response causes
Ahsg/fetuin down-regulation, every possible effort shouldabove, Ahsg/fetuin is regulated as a negative acute-phase
reactant [16] and may, thus, represent a missing link be implemented to avoid potential pro-inflammatory
stimuli during hemo- or peritoneal dialysis proceduresbetween chronic inflammation and vascular calcification.
In this study, Ahsg/fetuin serum concentrations were (e.g., by choice of membranes, quality of dialysates and
dialysis solutions). The recently suggested role of statinslower in hemodialysis patients compared with healthy
controls, and low levels were associated with increased as anti-inflammatory drugs in the context of atherogene-
sis will have to be evaluated [18].CRP levels, increased cardiovascular mortality, and all-
cause mortality. Multivariate analysis identified Ahsg/
fetuin-deficiency as an inflammation-dependent mortal-
CONCLUSIONity risk factor in the dialysis population.
Calcium-regulatory proteins, including MGP andWe further measured the functional calcium/phos-
Ahsg/fetuin, are important and potent inhibitors of vas-phate precipitation inhibitory capacity of patient sera by
cular calcification in vivo. In dialysis patients, Ahsg/fet-using a 45CaCl2-radioisotope assay in a subgroup of 8 di-
uin deficiency is associated with inflammation and linksalysis patients with low serum Ahsg/fetuin levels. These
vascular calcification to mortality in dialysis patients.sera showed a significantly impaired ex vivo capacity to
Data on the role of MGP in uremic cardiovascular dis-inhibit calcium/phosphate precipitation. The relevance
ease are still inconclusive, but MGP may be an importantof Ahsg/fetuin in this context was proven by reconstitu-
candidate molecule in the pathogenesis of arterial mediation of these sera with purified Ahsg/fetuin. This maneu-
calcification. Notably, the possibility that increased vita-ver was able to normalize precipitation inhibition. Figure
min K intake may induce the synthesis of more active1 shows an example of an ECG-gated multislice spiral
MGP and, thus, increase the calcification-inhibitory po-CT to quantify coronary artery calcification performed
tential is a challenging perspective. The concept of cal-in one of these latter dialysis patients with low serum
cium-regulatory protein deficiencies does not questionAhsg/fetuin/levels and an impaired calcium/phosphate
the importance to treat hyperphosphatemia and hyper-precipitation inhibition.
calcemia as major prerequisites in the pathogenesis of
unwanted calcifications in uremia. Ahsg/fetuin levels
AHSG/FETUIN, MGP, AND CLINICAL may even help to guide and optimize phosphate-binder
CONSEQUENCES and vitamin D therapies. In the presence of normal or
high Ahsg/levels, a relative protection from precipitationWhat are the potential clinical and therapeutic conse-
quences when considering a major role of calcium-regu- despite the presence of an increased calcium x phosphate
ion product may prevail. In contrast, serum calcium andlatory protein deficiencies as a cardiovascular risk factor
in uremia? First, the appropriate assays must be estab- phosphate concentrations even in the upper normal
range may lead to aggravated precipitation when Ahsg/lished to enable risk-factor screening. In patients with
predominant media calcifications, screening for vitamin fetuin levels are very low.
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